1. Home
  2. CYCC vs MITQ Comparison

CYCC vs MITQ Comparison

Compare CYCC & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • MITQ
  • Stock Information
  • Founded
  • CYCC 1992
  • MITQ N/A
  • Country
  • CYCC Malaysia
  • MITQ United States
  • Employees
  • CYCC N/A
  • MITQ N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • MITQ Telecommunications Equipment
  • Sector
  • CYCC Health Care
  • MITQ Telecommunications
  • Exchange
  • CYCC Nasdaq
  • MITQ Nasdaq
  • Market Cap
  • CYCC 7.8M
  • MITQ 7.6M
  • IPO Year
  • CYCC N/A
  • MITQ 2021
  • Fundamental
  • Price
  • CYCC $16.04
  • MITQ $0.75
  • Analyst Decision
  • CYCC
  • MITQ
  • Analyst Count
  • CYCC 0
  • MITQ 0
  • Target Price
  • CYCC N/A
  • MITQ N/A
  • AVG Volume (30 Days)
  • CYCC 5.3M
  • MITQ 102.6K
  • Earning Date
  • CYCC 08-13-2025
  • MITQ 09-25-2025
  • Dividend Yield
  • CYCC N/A
  • MITQ N/A
  • EPS Growth
  • CYCC N/A
  • MITQ N/A
  • EPS
  • CYCC N/A
  • MITQ N/A
  • Revenue
  • CYCC $14,000.00
  • MITQ $18,613,000.00
  • Revenue This Year
  • CYCC $137.21
  • MITQ N/A
  • Revenue Next Year
  • CYCC N/A
  • MITQ N/A
  • P/E Ratio
  • CYCC N/A
  • MITQ N/A
  • Revenue Growth
  • CYCC N/A
  • MITQ N/A
  • 52 Week Low
  • CYCC $3.08
  • MITQ $0.50
  • 52 Week High
  • CYCC $597.60
  • MITQ $1.55
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 60.33
  • MITQ 58.78
  • Support Level
  • CYCC $10.05
  • MITQ $0.74
  • Resistance Level
  • CYCC $19.87
  • MITQ $0.76
  • Average True Range (ATR)
  • CYCC 3.57
  • MITQ 0.05
  • MACD
  • CYCC 1.99
  • MITQ 0.00
  • Stochastic Oscillator
  • CYCC 77.07
  • MITQ 68.80

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

Share on Social Networks: